Effects of single-dose neuropeptide Y on levels of hippocampal BDNF, MDA, GSH, and NO in a rat model of pentylenetetrazole-induced epileptic seizure

Abstract

Epilepsy is one of the most common neurological disorders, characterized by recurrent seizures, which may increase the content of reactive oxygen and nitrogen species. Th e objective of this study was to investigate the eff ects of Neuropeptide Y on oxidative and nitrosative balance and brain-derived neurotrophic factor levels induced by pentylenetetrazole (a standard convulsant drug) in the hippocampus of Wistar rats. Th ree groups of seven rats were treated intraperitoneally as follows: group  (saline + saline)  ml saline, group  (salin + Pentylenetetrazole)  ml saline  min before Pentylenetetrazole; and group  (Neuropeptide Y + Pentylenetetrazole)  μg/kg Neuropeptide Y  min before  mg/kg Pentylenetetrazole. After  h, the animals were euthanized by decapitation. Hippocampus were isolated to evaluate the malondialdehyde, glutathione, nitric oxide, and brain-derived neurotrophic factor levels in three rat groups. Th e results of this study demonstrated that while intraperitoneally administered neuropeptide Y did not result in a statistically signifi cant diff erence in BDNF levels, its administration caused a statistically signifi cant decrease in malondialdehyde and nitric oxide levels and an increase in glutathione levels in rats with pentylenetetrazole-induced epileptic seizure. Neuropeptide Y were able to reduce nitroxidative damage induced by pentylenetetrazole in the hippocampus of Wistar rats.©  Association of Basic Medical Sciences of FB&H. All rights reserved KEY WORDS: epileptic seizure, neuropeptide Y, brain-derived neurotrophic factor, oxidative stress, nitrosative stress

Nanotechnological advances in the treatment of epilepsy: a comprehensive review

“…However, there was no significant but considerable decrease in the level of BDNF in NPY-treated rats (285.8 ± 53.6 ng g −1 protein) in comparison to untreated rats of the group (ii) 377.9 ± 27.5 ng g −1 protein. All these data support the neuroprotective property of NPY [93] Galantamine is an alkaloid compound that acts as an acetylcholinesterase inhibitor and allosteric potentiator of nicotinic receptors. It has been investigated for its potential antiepileptic effects [94].…”

Upregulation of the lncRNA MEG3 improves cognitive impairment, alleviates neuronal damage, and inhibits activation of astrocytes in hippocampus tissues in Alzheimer's disease through inactivating the PI3K/Akt signaling pathway

“…Besides, MDA is involved in the production of oxygen free radicals (OFRs) that injure cellular membranes while those of SOD and GSH‐Px generated in cells and tissues of animals under the changing pathological conditions by acting as scavengers of OFRs . A previous study found that a single‐dose treatment with neuropeptide Y decreased the MDA level and enhanced GSH levels in rats with pentylenetetrazole‐induced epileptic seizures . Furthermore, astrocytes at neural synapses contribute to synaptogenesis through normally exhibiting increased apolipoprotein E expression and GFAP reactivity in neurodegenerative disease states .…”

“…44 A previous study found that a single-dose treatment with neuropeptide Y decreased the MDA level and enhanced GSH levels in rats with pentylenetetrazoleinduced epileptic seizures. 45 Furthermore, astrocytes at neural synapses contribute to synaptogenesis through normally exhibiting increased apolipoprotein E expression and GFAP reactivity in neurodegenerative disease states. 46 It can be explained by that when PC12 cells induced with the heat stress, GFAP levels were decreased, while PC12 cells, which are overexpressed in the gene encoding GFAP, showed resistance.…”

Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: a review

“…NPY can stimulate autophagy in mouse and rat hypothalamic neural cells by activating Y1R and Y5R [ 79 ]. Additionally, an A1-40 mouse model treated with exogenous NPY demonstrated reduced oxidative stress, and mitochondrial dysfunction, via blockade of NO production and reduced lipid peroxidation [ 80 , 81 ].…”